Impaired platelet P2Y12 inhibition by thienopyridines in chronic kidney disease: Mechanisms, clinical relevance and pharmacological options

Nephrology Dialysis Transplantation

Volumn 28, Issue 8, 2013, Pages 1994-2002

  Morel, Olivier ^a   Muller, Clotilde ^a   Jesel, Laurence ^a   Moulin, Bruno ^a   Hannedouche, Thierry ^a  

^a UNIVERSITÉ DE STRASBOURG   (France)

Author keywords

Percutaneous coronary; Platelet; Stent; Thienopyridines; Thrombosis

Indexed keywords

CILOSTAZOL; CLOPIDOGREL; PRASUGREL; PURINERGIC P2Y12 RECEPTOR; THIENOPYRIDINE DERIVATIVE; TICAGRELOR;

CHRONIC KIDNEY DISEASE; CLINICAL EFFECTIVENESS; DISEASE ACTIVITY; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENCY; HEMODIALYSIS; HIGH RISK PATIENT; HUMAN; ISCHEMIA; MOLECULAR DYNAMICS; MORTALITY; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PLATELET REACTIVITY; PREDICTION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SIGNAL TRANSDUCTION; STENT THROMBOSIS; THROMBOCYTE FUNCTION; THROMBOSIS; TREATMENT PLANNING;

PERCUTANEOUS CORONARY; PLATELET; STENT; THIENOPYRIDINES; THROMBOSIS;

ANIMALS; BLOOD PLATELETS; HUMANS; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RECEPTORS, PURINERGIC P2Y12; RENAL INSUFFICIENCY, CHRONIC; THIENOPYRIDINES;

EID: 84884540623     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gft027     Document Type: Review

References (68)

1. Tsai TT, Messenger JC, Brennan JM et al. Safety and efficacy of drug-eluting stents in older patients with chronic kidney disease: a report from the linked CathPCI Registry-CMS claims database. J Am Coll Cardiol 2011; 58: 1859-1869
2. Latif F, Kleiman NS, Cohen DJ et al. In-hospital and 1-year outcomes among percutaneous coronary intervention patients with chronic kidney disease in the era of drug-eluting stents: a report from the EVENT (Evaluation of Drug Eluting Stents and Ischemic Events) registry. JACC Cardiovasc Interv 2009; 2: 37-45
3. Sadeghi HM, Stone GW, Grines CL et al. Impact of renal insufficiency in patients undergoing primary angioplasty for acute myocardial infarction. Circulation 2003; 108: 2769-2775
4. Machecourt J, Danchin N, Lablanche JM et al. Risk factors for stent thrombosis after implantation of sirolimus-eluting stents in diabetic and nondiabetic patients: the EVASTENT Matched-Cohort Registry. J Am Coll Cardiol 2007; 50: 501-508
5. Briguori C, Airoldi F, Chieffo A et al. Renal function and drugeluting stent. Int J Cardiol 2010; 142: 92-94
6. Best PJ, Lennon R, Ting HH et al. The impact of renal insufficiency on clinical outcomes in patients undergoing percutaneous coronary interventions. J Am Coll Cardiol 2002; 39: 1113-1119
7. Montalescot G, Silvain J. Ticagrelor in the renal dysfunction subgroup: subjugated or substantiated? Circulation 2010; 122: 1049-1052
8. Morel O, El Ghannudi S, Jesel L et al. Cardiovascular mortality in chronic kidney disease patients undergoing percutaneous coronary intervention is mainly related to impaired P2Y12 inhibition by clopidogrel. J Am Coll Cardiol 2011; 57: 399-408
9. Htun P, Fateh-Moghadam S, Bischofs C et al. Low responsiveness to clopidogrel increases risk among CKD patients undergoing coronary intervention. J Am Soc Nephrol 2011; 22: 627-633
10. James S, Budaj A, Aylward P et al. Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation 2010; 122: 1056-1067
11. Sreedhara R, Itagaki I, Hakim RM. Uremic patients have decreased shear-induced platelet aggregation mediated by decreased availability of glycoprotein IIb-IIIa receptors. Am J Kidney Dis 1996; 27: 355-364
12. Gawaz MP, Dobos G, Spath M et al. Impaired function of platelet membrane glycoprotein IIb-IIIa in end-stage renal disease. J Am Soc Nephrol 1994; 5: 36-46
13. Escolar G, Diaz-Ricart M, Cases A et al. Abnormal cytoskeletal assembly in platelets from uremic patients. Am J Pathol 1993; 143: 823-831
14. Noris M, Benigni A, Boccardo P et al. Enhanced nitric oxide synthesis in uremia: implications for platelet dysfunction and dialysis hypotension. Kidney Int 1993; 44: 445-450
15. Brunini TM, Mendes-Ribeiro AC, Ellory JC et al. Platelet nitric oxide synthesis in uremia and malnutrition: a role for L-arginine supplementation in vascular protection? Cardiovasc Res 2007; 73: 359-367
16. Soslau G, Brodsky I, Putatunda B et al. Selective reduction of serotonin storage and ATP release in chronic renal failure patients platelets. Am J Hematol 1990; 35: 171-178
17. Brophy DF, Martin EJ, Carr SL, Jr et al.. The effect of uremia on platelet contractile force, clot elastic modulus and bleeding time in hemodialysis patients. Thromb Res 2007; 119: 723-729
18. Bonomini M, Dottori S, Amoroso L et al. Increased platelet phosphatidylserine exposure and caspase activation in chronic uremia. J Thromb Haemost 2004; 2: 1275-1281
19. Morel O, Jesel L, Freyssinet JM et al. Cellular mechanisms underlying the formation of circulating microparticles. Arterioscler Thromb Vasc Biol 2011; 31: 15-26
20. Woo JS, Kim W, Lee SR et al. Platelet reactivity in patients with chronic kidney disease receiving adjunctive cilostazol compared with a high-maintenance dose of clopidogrel: Results of the Effect of Platelet Inhibition According to Clopidogrel Dose in Patients with Chronic Kidney Disease (PIANO-2 CKD) randomized study. Am Heart J 2011; 162: 1018-1025
21. Amabile N, Guerin AP, Leroyer A et al. Circulating endothelial microparticles are associated with vascular dysfunction in patients with end-stage renal failure. J Am Soc Nephrol 2005; 16: 3381-3388
22. Thijs A, Nanayakkara PW, Ter Wee PM et al. Mild-to-moderate renal impairment is associated with platelet activation: a crosssectional study. Clin Nephrol 2008; 70: 325-331
23. Ballow A, Gader AM, Huraib S et al. Platelet surface receptor activation in patients with chronic renal failure on hemodialysis, peritoneal dialysis and those with successful kidney transplantation. Platelets 2005; 16: 19-24
24. Linthorst GE, Folman CC, van Olden RW et al. Plasma thrombopoietin levels in patients with chronic renal failure. Hematol J 2002; 3: 38-42
25. Best PJ, Steinhubl SR, Berger PB et al. The efficacy and safety of short-and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. Am Heart J 2008; 155: 687-693
26. Dasgupta A, Steinhubl SR, Bhatt DL et al. Clinical outcomes of patients with diabetic nephropathy randomized to clopidogrel plus aspirin versus aspirin alone (a post hoc analysis of the clopidogrel for high atherothrombotic risk and ischemic stabilization, management, and avoidance [CHARISMA] trial). Am J Cardiol 2009; 103: 1359-1363
27. Deray G, Bagnis C, Brouard R et al. Clopidogrel activities in patients with renal function impairment. Clin Drug Investig 1998; 16: 319-328
28. Cuisset T, Frere C, Moro PJ et al. Lack of effect of chronic kidney disease on clopidogrel response with high loading and maintenance doses of clopidogrel after Acute Coronary Syndrome. Thromb Res 2010; 126: e400-e402
29. Kaufman JS, Fiore L, Hasbargen JA et al. A pharmacodynamic study of clopidogrel in chronic hemodialysis patients. J Thromb Thrombolysis 2000; 10: 127-131
30. Park SH, Kim W, Park CS et al. A comparison of clopidogrel responsiveness in patients with versus without chronic renal failure. Am J Cardiol 2009; 104: 1292-1295
31. Angiolillo DJ, Bernardo E, Capodanno D et al. Impact of chronic kidney disease on platelet function profiles in diabetes mellitus patients with coronary artery disease taking dual antiplatelet therapy. J Am Coll Cardiol 2010; 55: 1139-1146
32. Fox CS, Larson MG, Leip EP et al. Glycemic status and development of kidney disease: the Framingham Heart Study. Diabetes Care 2005; 28: 2436-2440
33. Angiolillo DJ. Variability in responsiveness to oral antiplatelet therapy. Am J Cardiol 2009; 103: 27A-34A
34. El Ghannudi S, Ohlmann P, Jesel L et al. Impaired inhibition of P2Y(12) by clopidogrel is a major determinant of cardiac death in diabetes mellitus patients treated by percutaneous coronary intervention. Atherosclerosis 2011; 217: 465-472
35. Muller C, Caillard S, Jesel L et al. Association of estimated GFR with platelet inhibition in patients treated with clopidogrel. Am J Kidney Dis 2012; 59: 777-785
36. Aleil B, Ravanat C, Cazenave JP et al. Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases. J Thromb Haemost 2005; 3: 85-92
37. Geisler T, Grass D, Bigalke B et al. The Residual Platelet Aggregation after Deployment of Intracoronary Stent (PREDICT) score. J Thromb Haemost 2008; 6: 54-61
38. Dreisbach AW. The influence of chronic renal failure on drug metabolism and transport. Clin Pharmacol Ther 2009; 86: 553-556
39. Gugliucci A, Kinugasa E, Kotani K et al. Serum paraoxonase 1 (PON1) lactonase activity is lower in end-stage renal disease patients than in healthy control subjects and increases after hemodialysis. Clin Chem Lab Med 2011; 49: 61-67
40. Touchette MA, Slaughter RL. The effect of renal failure on hepatic drug clearance. Ann Pharmacother 1991; 25: 1214-1224
41. Leblond F, Guevin C, Demers C et al. Downregulation of hepatic cytochrome P450 in chronic renal failure. J Am Soc Nephrol 2001; 12: 326-332
42. Small DS, Wrishko RE, Ernest CS, II et al. Prasugrel pharmacokinetics and pharmacodynamics in subjects with moderate renal impairment and end-stage renal disease. J Clin Pharm Ther 2009; 34: 585-594
43. Jankowski V, Gunthner T, Herget-Rosenthal S et al. Dinucleoside polyphosphates and uremia. Semin Dial 2009; 22: 396-399
44. Chang H, Yanachkov IB, Michelson AD et al. Agonist and antagonist effects of diadenosine tetraphosphate, a platelet dense granule constituent, on platelet P2Y1, P2Y12 and P2X1 receptors. Thromb Res 2010; 125: 159-165
45. Jankowski J, Hagemann J, Yoon MS et al. Increased vascular growth in hemodialysis patients induced by platelet-derived diadenosine polyphosphates. Kidney Int 2001; 59: 1134-1141
46. Keltai M, Tonelli M, Mann JF et al. Renal function and outcomes in acute coronary syndrome: impact of clopidogrel. Eur J Cardiovasc Prev Rehabil 2007; 14: 312-318
47. Ang L, Palakodeti V, Khalid A et al. Elevated plasma fibrinogen and diabetes mellitus are associated with lower inhibition of platelet reactivity with clopidogrel. J Am Coll Cardiol 2008; 52: 1052-1059
48. Geisler T, Mueller K, Aichele S et al. Impact of inflammatory state and metabolic control on responsiveness to dual antiplatelet therapy in type 2 diabetics after PCI: prognostic relevance of residual platelet aggregability in diabetics undergoing coronary interventions. Clin Res Cardiol 2010; 99: 743-752
49. Morel O, El Ghannudi S, Hess S et al. The extent of P2Y12 inhibition by clopidogrel in diabetes mellitus patients with acute coronary syndrome is not related to glycaemic control: Roles of white blood cell count and body weight. Thromb Haemost 2012; 108: 338-348
50. Hermann A, Rauch BH, Braun M et al. Platelet CD40 ligand (CD40L)-subcellular localization, regulation of expression, and inhibition by clopidogrel. Platelets 2001; 12: 74-82
51. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E et al. Clopidogrel withdrawal is associated with proinflammatory and prothrombotic effects in patients with diabetes and coronary artery disease. Diabetes 2006; 55: 780-784
52. Diehl P, Olivier C, Halscheid C et al. Clopidogrel affects leukocyte dependent platelet aggregation by P2Y12 expressing leukocytes. Basic Res Cardiol 2010; 105: 379-387
53. Grau AJ, Boddy AW, Dukovic DA et al. Leukocyte count as an independent predictor of recurrent ischemic events. Stroke 2004; 35: 1147-1152
54. O'Donoghue M, Morrow DA, Cannon CP et al. Association between baseline neutrophil count, clopidogrel therapy, and clinical and angiographic outcomes in patients with STelevation myocardial infarction receiving fibrinolytic therapy. Eur Heart J 2008; 29: 984-991
55. Bhatt DL, Flather MD, Hacke W et al. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol 2007; 49: 1982-1988
56. Weber M, Bhatt DL, Brennan DM et al. High-sensitivity C-reactive protein and clopidogrel treatment in patients at high risk of cardiovascular events: a substudy from the CHARISMA trial. Heart 2011; 97: 626-631
57. von Beckerath N, Kastrati A, Wieczorek A et al. A double-blind, randomized study on platelet aggregation in patients treated with a daily dose of 150 or 75 mg of clopidogrel for 30 days. Eur Heart J 2007; 28: 1814-1819
58. Price MJ, Berger PB, Teirstein PS et al. Standard-vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA 2011; 305: 1097-1105
59. Trenk D, Stone GW, Gawaz M et al. A Randomized Trial of Prasugrel Versus Clopidogrel in Patients With High Platelet Reactivity on Clopidogrel After Elective Percutaneous Coronary Intervention With Implantation of Drug-Eluting Stents: Results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) Study. J Am Coll Cardiol 2012; 59: 2159-2164
60. Wiviott SD, Braunwald E, McCabe CH et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001-2015
61. Wiviott SD, Braunwald E, McCabe CH et al. Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial. Lancet 2008; 371: 1353-1363
62. Wiviott SD, Braunwald E, Angiolillo DJ et al. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38. Circulation 2008; 118: 1626-1636
63. Alexopoulos D, Panagiotou A, Xanthopoulou I et al. Antiplatelet effects of prasugrel vs. double clopidogrel in patients on hemodialysis and with high on-treatment platelet reactivity. J Thromb Haemost 2011; 9: 2379-2385
64. Gurbel PA, Bliden KP, Butler K et al. Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study. Circulation 2010; 121: 1188-1199
65. Alexopoulos D, Galati A, Xanthopoulou I et al. Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study. J Am Coll Cardiol 2012; 60: 193-199
66. Wallentin L, Becker RC, Budaj A et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361: 1045-1057
67. Husted S, van Giezen JJ. Ticagrelor: the first reversibly binding oral P2Y12 receptor antagonist. Cardiovasc Ther 2009; 27: 259-274
68. Alexopoulos D, Xanthopoulou I, Plakomyti TE et al. Ticagrelor in clopidogrel-resistant patients undergoing maintenance hemodialysis. Am J Kidney Dis 2012; 60: 332-333